Documents
Application Sponsors
Marketing Status
Application Products
| 001 | SOLUTION;INTRAVENOUS | 400MG/250ML (1.6MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | 1 | AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER | MOXIFLOXACIN HYDROCHLORIDE |
FDA Submissions
| TYPE 3; Type 3 - New Dosage Form | ORIG | 1 | AP | 2001-11-30 | STANDARD |
| LABELING; Labeling | SUPPL | 2 | AP | 2002-06-12 | STANDARD |
| LABELING; Labeling | SUPPL | 3 | AP | 2002-05-16 | STANDARD |
| MANUF (CMC); Manufacturing (CMC) | SUPPL | 5 | AP | 2002-12-10 | STANDARD |
| LABELING; Labeling | SUPPL | 6 | AP | 2003-02-28 | STANDARD |
| EFFICACY; Efficacy | SUPPL | 7 | AP | 2003-02-28 | STANDARD |
| LABELING; Labeling | SUPPL | 9 | AP | 2003-02-28 | STANDARD |
| LABELING; Labeling | SUPPL | 11 | AP | 2003-10-06 | STANDARD |
| EFFICACY; Efficacy | SUPPL | 17 | AP | 2004-05-18 | PRIORITY |
| LABELING; Labeling | SUPPL | 18 | AP | 2004-03-06 | STANDARD |
| LABELING; Labeling | SUPPL | 19 | AP | 2004-07-28 | STANDARD |
| EFFICACY; Efficacy | SUPPL | 22 | AP | 2005-06-13 | STANDARD |
| EFFICACY; Efficacy | SUPPL | 24 | AP | 2005-11-22 | UNKNOWN |
| LABELING; Labeling | SUPPL | 25 | AP | 2005-11-22 | STANDARD |
| LABELING; Labeling | SUPPL | 30 | AP | 2007-05-31 | STANDARD |
| LABELING; Labeling | SUPPL | 31 | AP | 2008-02-15 | STANDARD |
| LABELING; Labeling | SUPPL | 33 | AP | 2008-12-29 | STANDARD |
| LABELING; Labeling | SUPPL | 34 | AP | 2008-10-03 | STANDARD |
| LABELING; Labeling | SUPPL | 35 | AP | 2009-06-24 | STANDARD |
| LABELING; Labeling | SUPPL | 36 | AP | 2009-04-27 | STANDARD |
| LABELING; Labeling | SUPPL | 38 | AP | 2010-10-25 | STANDARD |
| LABELING; Labeling | SUPPL | 39 | AP | 2009-11-24 | UNKNOWN |
| LABELING; Labeling | SUPPL | 40 | AP | 2010-03-02 | UNKNOWN |
| LABELING; Labeling | SUPPL | 41 | AP | 2011-02-25 | 901 REQUIRED |
| LABELING; Labeling | SUPPL | 46 | AP | 2011-10-18 | UNKNOWN |
| REMS; REMS | SUPPL | 49 | AP | 2011-08-03 | N/A |
| LABELING; Labeling | SUPPL | 50 | AP | 2011-10-18 | UNKNOWN |
| LABELING; Labeling | SUPPL | 52 | AP | 2012-08-24 | STANDARD |
| LABELING; Labeling | SUPPL | 53 | AP | 2012-12-18 | STANDARD |
| LABELING; Labeling | SUPPL | 54 | AP | 2013-08-14 | 901 REQUIRED |
| LABELING; Labeling | SUPPL | 55 | AP | 2014-11-20 | STANDARD |
| EFFICACY; Efficacy | SUPPL | 56 | AP | 2015-05-08 | STANDARD |
| EFFICACY; Efficacy | SUPPL | 57 | AP | 2016-09-27 | PRIORITY |
| LABELING; Labeling | SUPPL | 58 | AP | 2016-09-27 | STANDARD Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs. |
| LABELING; Labeling | SUPPL | 59 | AP | 2016-07-26 | STANDARD |
| LABELING; Labeling | SUPPL | 60 | AP | 2018-10-18 | STANDARD |
| LABELING; Labeling | SUPPL | 61 | AP | 2019-05-03 | STANDARD |
| LABELING; Labeling | SUPPL | 62 | AP | 2020-05-06 | STANDARD |
Submissions Property Types
| SUPPL | 5 | Null | 0 |
| SUPPL | 36 | Null | 7 |
| SUPPL | 38 | Null | 6 |
| SUPPL | 39 | Null | 6 |
| SUPPL | 40 | Null | 6 |
| SUPPL | 41 | Null | 6 |
| SUPPL | 46 | Null | 15 |
| SUPPL | 49 | Null | 7 |
| SUPPL | 50 | Null | 7 |
| SUPPL | 52 | Null | 7 |
| SUPPL | 53 | Null | 7 |
| SUPPL | 54 | Null | 15 |
| SUPPL | 55 | Null | 6 |
| SUPPL | 56 | Null | 7 |
| SUPPL | 57 | Null | 4 |
| SUPPL | 58 | Null | 7 |
| SUPPL | 59 | Null | 15 |
| SUPPL | 60 | Null | 6 |
| SUPPL | 61 | Null | 6 |
| SUPPL | 62 | Null | 6 |
CDER Filings
cder:Array
(
[0] => Array
(
[ApplNo] => 21277
[companyName] =>
[docInserts] => ["",""]
[products] => []
[labels] =>
[originalApprovals] => []
[supplements] =>
[actionDate] => 0000-00-00
)
)